Our findings, which are supported by two independent lymphoma patient datasets (Fig. 1B), propose PDGFRβ is yet another potent kinase in the list of regulators of IL-10 expression in ALCL and that targeting the PDGFRβ/STAT5/IL-10 axis is an attractive therapeutic strategy. The gene discussed is PDGFRB; the disease is anaplastic large cell lymphoma.